Corpora Cavernosa & How Traction Affects Erectile Tissue

Corpora cavernosa are two paired cylindrical erectile chambers that run the full length of the penile shaft, from the pubic bone to the glans. Each corpus cavernosum contains a network of sinusoidal spaces lined with endothelium and surrounded by smooth muscle tissue. The classic anatomical reference Gray's Anatomy describes the corpora cavernosa as the primary structural determinants of penile rigidity and erect penile dimensions.

The tunica albuginea — a dense, bi-layered fibrous sheath — encloses each corpus cavernosum. Hsu and colleagues, publishing in the Journal of Urology in 1994, described the tunica albuginea as a structure with an inner circular layer and an outer longitudinal layer that together provide both rigidity and elasticity to the corpora cavernosa during erection. The tunica albuginea transmits mechanical forces directly to the underlying corpora cavernosa tissue.

The corpus spongiosum is the third erectile chamber of the penis. Unlike the corpora cavernosa, the corpus spongiosum surrounds the urethra and has a thinner tunica wall. The corpus spongiosum does not contribute significantly to penile rigidity. Erect penile size — both length and girth — depends primarily on corpora cavernosa volume capacity, not on the corpus spongiosum.

Erection begins when nitric oxide is released from nerve terminals and endothelial cells within the corpora cavernosa. Burnett, publishing in the Journal of Urology in 1997 (PMID: 9006887), established that nitric oxide is the principal neurotransmitter mediating penile erection. Nitric oxide activates the enzyme guanylate cyclase, which produces cyclic GMP, triggering smooth muscle relaxation throughout the corpora cavernosa.

Smooth muscle relaxation within the corpora cavernosa allows the sinusoidal spaces to expand and fill with arterial blood. Helicine arteries — small coiled arteries branching from the deep penile arteries — deliver blood directly into the sinusoidal spaces of each corpus cavernosum. Lue, writing in the New England Journal of Medicine in 2000 (PMID: 10642549), described the corpora cavernosa erection mechanism as a hydraulic event dependent on arterial inflow and sinusoidal compliance.

The veno-occlusive mechanism is the process that maintains penile rigidity after the corpora cavernosa fill with blood. As the sinusoidal spaces expand, the engorged corpora cavernosa compress subtunical venules against the tunica albuginea — trapping blood within the erectile chambers. Penile rigidity depends on both the volume of blood the corpora cavernosa can hold and the integrity of the veno-occlusive mechanism that prevents venous outflow.

Erect penile size is directly proportional to corpora cavernosa blood-holding capacity. Larger corpora cavernosa volume means greater blood accumulation during the erectile process, resulting in greater erect length and erect girth. Any intervention that permanently increases corpora cavernosa volume — through new smooth muscle cell growth and new sinusoidal space formation — produces a corresponding increase in erect penile dimensions.

Natural blood flow to the penis depends on the nitric oxide signaling pathway — the body's primary physiological mechanism for directing arterial blood into the corpora cavernosa during sexual arousal. Healthy endothelial function, cardiovascular fitness, and adequate nitric oxide production all support natural blood flow to penile erectile tissue. Penile traction therapy complements natural blood flow by permanently increasing the corpora cavernosa's structural capacity to hold blood — generating new smooth muscle tissue and new sinusoidal spaces that allow greater blood accumulation during each erection, independent of changes in blood flow volume alone.

Penile traction therapy applies sustained, calibrated mechanical force along the penile shaft. The traction force transmits through the tunica albuginea directly to the underlying corpora cavernosa tissue. The biological process of mechanotransduction — the cellular response to mechanical force — converts sustained traction into a cascade of growth signals within corpora cavernosa smooth muscle cells and fibroblasts.

Sustained mechanical loading stimulates smooth muscle cell proliferation within the corpora cavernosa. Smooth muscle cell proliferation means the corpora cavernosa generate new cells — not simply stretching existing tissue. Fibroblasts within the corpora cavernosa respond to traction by producing new collagen and extracellular matrix proteins, a process known as collagen remodeling. New collagen fibers align along the axis of applied force, reinforcing the structural expansion of each corpus cavernosum.

New sinusoidal space formation is a critical outcome of traction-induced corpora cavernosa expansion. As smooth muscle cells proliferate and the connective tissue framework expands, additional sinusoidal spaces develop within the corpora cavernosa. Additional sinusoidal spaces increase the total blood-holding capacity of each corpus cavernosum — producing a permanent increase in both erect length and erect girth.

The principle of tissue expansion — a well-established medical technique used in reconstructive surgery — explains how sustained, sub-threshold mechanical force causes permanent biological tissue growth. Penile traction therapy applies the same tissue expansion principle to corpora cavernosa tissue, using graduated force over weeks and months to produce measurable, lasting structural changes in the erectile chambers.

Gontero and colleagues, publishing in BJU International in 2009 (PMID: 19170867), conducted a prospective study of penile extender use and reported a mean length gain of 1.3 cm (0.5 in) after six months of daily use. The Gontero study measured penile dimensions at regular intervals and confirmed that penile traction therapy produces progressive, sustained gains consistent with structural tissue expansion — including expansion of corpora cavernosa tissue.

Nikoobakht and colleagues, publishing in the Journal of Sexual Medicine in 2011 (PMID: 21054792), demonstrated a mean gain of 1.7 cm (0.67 in) in both flaccid and stretched penile length with a penile extender device. The Nikoobakht study confirmed that gains from penile traction therapy occur across both resting and stretched states, indicating genuine structural change in the corpora cavernosa rather than temporary engorgement. These findings are part of a broader evidence base — for comprehensive coverage, see clinical studies and evidence for penile traction therapy.

Corpora cavernosa volume determines both penile length and penile girth in the erect state. The expansion ratio from flaccid to erect depends on how much blood the corpora cavernosa sinusoidal spaces can accommodate. Men with greater corpora cavernosa smooth muscle content and larger sinusoidal networks achieve greater expansion during erection — resulting in larger erect penile dimensions.

Traction-induced corpora cavernosa expansion produces permanent structural gains, unlike temporary methods of erectile enlargement. Vacuum erection devices and oral vasodilators increase blood flow to the corpora cavernosa temporarily — creating short-term engorgement without new tissue growth. Penile traction therapy generates new smooth muscle cells and new sinusoidal spaces within the corpora cavernosa, producing gains that persist even without continued device use.

The permanence of traction-induced corpora cavernosa expansion is supported by the biological mechanism. New smooth muscle cells integrate into the existing sinusoidal architecture of the corpora cavernosa. New connective tissue and collagen fibers reinforce the expanded structure. Anderson, writing on the histology of penile erectile tissue in 2011, confirmed that cellular proliferation and matrix remodeling produce lasting structural changes in corpora cavernosa tissue when sustained mechanical loading is applied over weeks to months.

SizeGenetics is the FDA-registered Class II penile traction device engineered to deliver targeted mechanical force directly to corpora cavernosa tissue — stimulating the smooth muscle cell proliferation and sinusoidal expansion that produce permanent, measurable penile lengthening. Manufactured by Danamedic ApS in Denmark, the SizeGenetics device applies calibrated traction along the full length of the penile shaft, distributing force evenly across both corpora cavernosa. Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the penile traction device, designed the force distribution system based on principles of tissue mechanics directly relevant to corpora cavernosa anatomy.

The SizeGenetics device delivers adjustable traction force from 900 up to 3,200 grams (8.8 to 31.4 Newtons), with a graduated treatment protocol starting at lower tension and increasing progressively. The graduated protocol allows corpora cavernosa tissue to adapt to mechanical loading incrementally — preventing tissue damage while maximizing the smooth muscle cell proliferation and sinusoidal expansion that produce permanent gains. The 58-way Multi-Axis Comfort Technology ensures sustained daily wear of 4–6 hours over 3–6 months.

Force transmission from the SizeGenetics device follows a specific anatomical pathway: the device applies longitudinal traction to the penile shaft, the tunica albuginea transmits mechanical force to the enclosed corpora cavernosa, and corpora cavernosa smooth muscle cells and fibroblasts activate mechanotransduction signaling cascades. Controlled force distribution prevents localized tissue damage while producing uniform corpora cavernosa expansion along the full length of each corpus cavernosum.

The corpora cavernosa are central to understanding how penile traction therapy produces measurable, permanent results. The following pages explore the mechanism, clinical evidence, and related topics in depth.